Horizon Discovery Group plc (LSE:HZD) (Horizon), the international life science company supplying research tools and services that power genomics research and the development of personalized medicines, today announced it has introduced a unique range of genetically defined, highly characterized HDx Reference Standards for Immunohistochemistry (IHC) assays. The product range has been developed by Horizon’s diagnostics division.
The introduction of IHC HDx Reference Standards provides histopathology laboratories with a consistent and reproducible source of reference material for the development and quality control of IHC assays. The independent external controls contain precisely defined protein expression levels presented on one slide, providing scientists the ability to easily determine the sensitivity of their assay. These standards are unique in having undergone a high level of characterization at a molecular and protein level, including Quantitative Digital Pathology (QDP), to quantify the intensity of staining.
Variability in the quality of clinical samples and immunohistochemistry staining is ...
